Bethany Sensenig, Mba, Cma Email & Phone Number

Boston, Ma, Us

As CFO and Head of Operations, I work closely with the CEO, executive leadership team, and Board of Directors on strategies to maximize revenue, EBITDA, and shareholder value and equip them with data-informed recommendations to drive decisions around capital management, structure and allocation. Oversee Finance, Supply Chain, Quality, Pharmaceutical Science, IT and Facilities.

Boston, Ma, Us

Radius Health, Inc. is a biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and other related areas. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture, and in December 2022 to increase bone density in men with osteoporosis at high risk for fracture. In 2023, Radius also licensed the US rights to distribute BINOSTO® (alendronate sodium) effervescent tablet for oral solution, further expanding the Company’s presence in bone health.

Rockville, Maryland, Us

Supernus Pharmaceuticals (Nasdaq: SUPN) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.

9 Meters Biopharma, Inc. is a publicly-traded clinical-stage company pioneering novel treatments for people with rare digestive diseases, GI conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. 9 Meters is developing vurolenatide, a proprietary Phase 2 long-acting GLP-1 agonist, for SBS; larazotide, a tight junction regulator for MIS-C; and several near clinical-stage assets.As a key executive and officer at 9 Meters, I was a financial advisor to the business, partnering with CEO & Board on business strategy, BD opportunities, and financing strategy and execution. I led a team of people responsible for SEC reporting, including 10K, 10Q, 8K, Annual Proxy, and more. In addition to overseeing accounting and financial reporting, I focused on development and execution of capital raises, raising $75M in debt/equity capital. while seeking to optimize our institutional shareholder base and extend cash runway. I closely managed banking relationships (cash/treasury/investment), annual and quarterly audits, evaluated potential areas of risk for the company, and led the development and execution of the company’s annual budget and long-range strategic and financial plans.

Haifa, Israel , Il

Minovia Therapeutics is a clinical-stage, Israel-based biotech company doing breakthrough work as the first to use mitochondrial cell therapy to treat rare mitochondrial diseases. Learn more about Minovia's novel Mitochondrial Augmentation Technology (MAT) platform at: www.minoviatx.com.In this highly strategic, dual role, I was leading as the Company’s top US-based executive, partnering with the CEO and Exec Chairman on business and financial strategy, while building the startup’s foundation for sustainable, scalable growth. For the US, I put together a team spanning manufacturing, quality, medical, and clinical development (with the rest of 45 employees in Israel and Switzerland). As CFO, I was responsible for fundraising, investor relations, and establishing key banking relationships; leading business development for strategic industry partnerships, including generating leads, analyzing term sheets, negotiation, valuation, and financial modeling; and securing both equity and non-dilutive funding. I developed and implemented tax strategies across Israel, US and Switzerland, while building the foundational elements of finance and accounting functions (US GAAP), including ERP implementation, internal controls, annual budgeting, quarterly forecasts, and financial reporting.As Head of US Operations, I was responsible for hiring, team development, and a diverse and inclusive culture. Through interactions with hospitals, I also helped in establishing key relationships with mitochondrial disease experts and KOLs. Equally critical was ensuring CMC readiness in the US, including the buildout of US cGMP cell therapy manufacturing capacity outside of Boston, oversight of US Quality Operations, and serving as Sponsor’s Authorized Representative to the FDA.

Cambridge, Ma, Us

In this executive role, I managed over $1B P&L, overseeing both Finance and Commercial Operations in 30+ countries spanning the US, Asia-Pacific, Latin America, and Europe, including a ~400-person Commercial team with 5 direct reports and 30-person Finance team with 7 direct-reports. I held accountability for top-line, gross margin, and operating margin performance, with focus on growing the business while delivering a leveraged P&L.Additionally, I drove commercial expansion for Specialty Medicine and Rare Disease products into select markets across Latin America and Asia-Pacific, including Japan, China, South Korea, Taiwan, Hong Kong, Australia, and NZ, with 9 figures in annual revenue. Simultaneously, I led the Biosimilars Business in Europe, growing it more than 3X in 1 year while managing a 9-figure P&L. As a finance partner to multiple executives, I further supported the global product strategy from Ph II/III to commercial assets.Given my global remit, I often presented at Biogen’s quarterly BOD meetings, fielding questions on budget and business and garnered board approval for top-line revenue, expansion and business development across regions/markets. I also established board-level reporting – providing the C-suite and board of directors with a succinct dashboard of KPIs for the company's global expansion investment.

Cambridge, Ma, Us

In this role, I provided strategic and operational financial planning, reporting, and decision support to the Chief Commercial Officer for Biogen's consolidated Commercial Operations, with $10B+ in annual revenue and $1B in annual OPEX. During this time, I was promoted and assumed responsibility for Commercial Operations for APAC, LATAM, and the Biosimilars Business in Europe (starting 2017), leading 400+ employees.For the commercial expansion countries, I owned P&Ls of over $500M spanning LATAM, APAC, and Biosimilars in Europe, including a joint venture with Samsung Bioepis ($310M deal – earning ~$1B in revenue over 3-4 years). As a strategic commercial partner, I collaborated with the EVP/Chief Commercial Officer to drive market share growth, product revenue, and long-term strategic initiatives.

Cambridge, Ma, Us

In this function, I led Finance operations for the global Pharmaceutical Operations and Technology (PO&T) division with over $1.7B in annual operating expense and $1.3B+ in Cost of Goods Sold. I also served as the division's finance business partner, while providing financial vision and direction for a 10-person Finance team. More specifically, I developed PO&T’s financial forecasts, annual operating plan, and long-range plan through deep business knowledge – acting as strategic advisor and business partner to the division’s executive VP. I am well-versed in understanding cGMP and GMP manufacturing processes, Quality systems, and CMC/Reg requirements at different product stages. I also oversaw financial modeling and due diligence for acquisitions, partnerships, and joint ventures, supporting negotiations for three plant/facility acquisitions totaling nearly $1B, while managing Biogen’s capital budget of $800M+, including analysis for real estate and lease transactions.

Cambridge, Ma, Us

As a strategic finance business partner for the IT and PO&T divisions, leveraged skills in strategy and analysis to develop 5-year long range plans, detailed financial forecasts, annual operating plans, quarterly business reviews, and detailed valuation support for business opportunities, investments, and other strategic initiatives.Supported R&D program teams for early and late-stage programs; provided financial reporting and business case analysis for short and long-term investments.

Cambridge, Ma, Us

Managed $350M+ in global inventory and global Cost of Sales activity of $500M. Supervised a team of managers and analysts supporting inventory accounting, expense forecasting, annual budgeting and financial reporting for Biogen's Global Quality organization and the Manufacturing leadership team for the RTP site.

Cambridge, Ma, Us

Cambridge, Ma, Us

Rahway, New Jersey, Us

Rahway, New Jersey, Us

Fletcher, Nc, Us

Masters, Business Administration

Bachelors Of Science, Accounting & Business Management